Twist Bioscience Co. (NASDAQ:TWST) Insider Dennis Cho Sells 806 Shares

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 806 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the sale, the insider now directly owns 112,221 shares of the company’s stock, valued at $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Dennis Cho also recently made the following trade(s):

• On Friday, January 3rd, Dennis Cho sold 144 shares of Twist Bioscience stock. The stock was sold at an average price of $45.59, for a total transaction of $6,564.96.
• On Friday, December 20th, Dennis Cho sold 316 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total transaction of $14,188.40.
• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The shares were sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The stock was sold at an average price of $52.70, for a total value of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $72,336.00.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $53.66 on Thursday. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The company has a fifty day simple moving average of $48.74 and a two-hundred day simple moving average of $46.27.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.75) EPS. Equities analysts expect that Twist Bioscience Co. will post -2.27 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of TWST. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience in the third quarter valued at $43,992,000. State Street Corp raised its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Wellington Management Group LLP lifted its stake in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Jennison Associates LLC boosted its holdings in Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC increased its stake in Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares during the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent analyst reports. Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Scotiabank upped their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a report on Tuesday. Wolfe Research initiated coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, TD Cowen restated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.